Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm PR Newswire - Thu Jun 4, 3:36PM CDT

NEW YORK , June 4, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NASDAQ:...

RARE : 22.79 (+5.56%)
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference GlobeNewswire - Wed Jun 3, 3:30PM CDT

NOVATO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious...

RARE : 22.79 (+5.56%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri May 22, 3:30PM CDT

NOVATO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare...

RARE : 22.79 (+5.56%)
Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference GlobeNewswire - Wed May 6, 3:30PM CDT

NOVATO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious...

RARE : 22.79 (+5.56%)
Ultragenyx: Q1 Earnings Snapshot AP - Tue May 5, 3:07PM CDT

Ultragenyx: Q1 Earnings Snapshot

RARE : 22.79 (+5.56%)
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update GlobeNewswire - Tue May 5, 3:01PM CDT

First quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760...

RARE : 22.79 (+5.56%)
Ultragenyx's Conference Call Tomorrow: Still Waiting for Gene Therapy to Pay Rent Barchart - Mon May 4, 4:26PM CDT

Barchart Research What to Expect from RARE Earnings RARE Generated May 4, 2026 Current Price $24.81 EPS Estimate $$-1.55 Consensus Rating Strong Buy Average Move 5.39% Ultragenyx's Conference Call Tomorrow:...

RARE : 22.79 (+5.56%)
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update GlobeNewswire - Wed Apr 29, 7:00AM CDT

NOVATO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious...

RARE : 22.79 (+5.56%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Apr 24, 3:30PM CDT

NOVATO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare...

RARE : 22.79 (+5.56%)
RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 Business Wire - Mon Apr 6, 8:26AM CDT

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their...

RARE : 22.79 (+5.56%)

Barchart Exclusives

Intel Stock Has Risen Sixfold from Its 2025 Lows, but Don’t Expect a Dividend Yet Barchart - Tue Jun 9, 6:30PM CDT
INTC's reversal of fortunes has been a huge boon to investors, but with capex spending still expected to remain high and customers' cash slow to accumulate, don't expect Intel to reinstate its dividend anytime soon. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.